Sam Brusco, Associate Editor03.22.22
Integra LifeSciences launched its NeuraGen 3D nerve guide matrix, a resorbable implant to repair peripheral nerve discontinuities. NeuraGen 3D creates an ideal environment to potentially allow more complete functional recovery after mid-gap nerve repair than hollow nerve conduits alone.
“For more than 30 years, Integra has been dedicated to researching and developing regenerative engineered collagen solutions for healthcare professionals and patients,” Integra exec VP and president of Tissue Technologies Robert T. Davis, Jr. told the press. “With NeuraGen 3D, we’re advancing peripheral nerve repair solutions through an innovative combination of Integra’s trusted bovine type 1 collagen and Integra Dermal Regeneration Template, a technology that many customers know and trust. The unique inner matrix of NeuraGen 3D has porous channels which has demonstrated preclinically to help guide Schwann cell migration and direct axonal growth, an important objective for surgeons in the treatment of nerve repair and restoring function. NeuraGen 3D is a great addition to our peripheral nerve repair portfolio and is designed to promote an optimized healing environment in short to mid-gap nerve repair, which may lead to more meaningful patient outcomes.”1
Integra’s NeuraGen and NeuraWrap have helped almost 200,000 patients suffering from nerve injuries, according to the company.
“I am very excited about the launch of NeuraGen 3D,” said Suhail Mithani, M.D., associate professor of Orthopedic and Plastic Surgery at Duke University, Division of Hand Surgery. “It’s the first product that has been designed and developed intelligently based upon our understanding of how nerves regenerate and will help bridge the gap between hollow conduit and allograft. NeuraGen 3D can really make a difference in terms of how we approach nerve repair and is a significant advancement in the treatment of peripheral nerve repair injuries.”
“The launch of NeuraGen 3D is a culmination of many years of research and a testament to the ongoing work of countless scientists and health care practitioners to develop cutting-edge solutions for the treatment of peripheral nerve injuries,” said Simon Archibald, Ph.D, vice president, chief scientist, Integra LifeSciences. “It’s Integra’s most innovative and advanced matrix product to come to market in several decades and has the potential to make a significant contribution to patient care.”
Reference
1 Data on file at Integra LifeSciences Corporation: 18-0447 MarketVision NeuraGen3D Exploratory Research June 2018.
“For more than 30 years, Integra has been dedicated to researching and developing regenerative engineered collagen solutions for healthcare professionals and patients,” Integra exec VP and president of Tissue Technologies Robert T. Davis, Jr. told the press. “With NeuraGen 3D, we’re advancing peripheral nerve repair solutions through an innovative combination of Integra’s trusted bovine type 1 collagen and Integra Dermal Regeneration Template, a technology that many customers know and trust. The unique inner matrix of NeuraGen 3D has porous channels which has demonstrated preclinically to help guide Schwann cell migration and direct axonal growth, an important objective for surgeons in the treatment of nerve repair and restoring function. NeuraGen 3D is a great addition to our peripheral nerve repair portfolio and is designed to promote an optimized healing environment in short to mid-gap nerve repair, which may lead to more meaningful patient outcomes.”1
Integra’s NeuraGen and NeuraWrap have helped almost 200,000 patients suffering from nerve injuries, according to the company.
“I am very excited about the launch of NeuraGen 3D,” said Suhail Mithani, M.D., associate professor of Orthopedic and Plastic Surgery at Duke University, Division of Hand Surgery. “It’s the first product that has been designed and developed intelligently based upon our understanding of how nerves regenerate and will help bridge the gap between hollow conduit and allograft. NeuraGen 3D can really make a difference in terms of how we approach nerve repair and is a significant advancement in the treatment of peripheral nerve repair injuries.”
“The launch of NeuraGen 3D is a culmination of many years of research and a testament to the ongoing work of countless scientists and health care practitioners to develop cutting-edge solutions for the treatment of peripheral nerve injuries,” said Simon Archibald, Ph.D, vice president, chief scientist, Integra LifeSciences. “It’s Integra’s most innovative and advanced matrix product to come to market in several decades and has the potential to make a significant contribution to patient care.”
Reference
1 Data on file at Integra LifeSciences Corporation: 18-0447 MarketVision NeuraGen3D Exploratory Research June 2018.
